Quarterly report pursuant to Section 13 or 15(d)

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 02, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	May 01, 2024	Jan. 17, 2019
Allowance for doubtful accounts		$ 0		$ 0		$ 0
Advertising costs		5,868	$ 25,846	30,076	$ 88,633
Impairment of intellectual property	$ 47,980	0	0	$ 0	47,980
Aging categories to estimate risk, description				The Company used the following aging categories to estimate the risk of delinquency status: (i) 0 days past due; (ii) 1-30 days past due; (iii) 31-60 days past due; (iv) 61-90 days past due; and (v) over 90 days past due
Impairment loss					47,980
Grant funding during the first year							$ 4,131,123	$ 2,842,430
Grant funding							11,029,977
Grant funding during the second year							3,638,268	2,831,838
Grant funding during the third year							$ 3,260,586	3,453,367
Grant additional funding during the third year								$ 99,431
Grant receivables		314,170		$ 314,170		76,266
Deferred income				0		$ 0
Grant income		572,777	300,985	1,204,407	790,140
Research and development expenses		$ 460,138	$ 286,962	$ 1,210,334	$ 762,768
Ownership percentage				50.00%
Royalty obligations description				The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation
Description of Non-Controlling Interest				Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest. Due to the Company’s retaining 75.8% ownership of BioCorRx Pharmaceuticals, Inc., 75.8% of BioCorRx Pharmaceuticals, Inc
Royalty obligations, net				$ 7,171,200
Minimum [Member]
Property plant and equipment estimated useful lives				5 years
Maximum [Member]
Property plant and equipment estimated useful lives				15 years